Name: Covidien Kendall Kangaroo ePump Pump Sets,1000ml, Bag,Each,773656
Brand: COVIDIEN/MEDTRONIC
SKU: 10200-40841
Price: 6.99 USD
Availability: InStock

Covidien Kendall Kangaroo ePump Pump Sets,1000ml, Bag,Each,773656 - 10200-40841

By COVIDIEN/MEDTRONIC

$6.99

(610 Reviews)

Model

10200-40841

Store

Health Products For You

Manufacturer

COVIDIEN/MEDTRONIC

Detail

Covidien Kendall Kangaroo ePump Pump Sets are DEHP-free and incorporate the anti-free flow safety feature. New PVC material eliminates the use of the compound or chemical DEHP (Di-Ethylhexyl Phthalate) which protects the patients from any adverse side effects associated with DEHP. These pump sets are compatible with Kendall Kangaroo EPump Enteral Feeding Pump and Kendall Kangaroo Joey Enteral Feeding Pump.Benefits of Covidien Kangaroo Feeding Sets for ePumpChemical freeMaterial: PVCProvide patient safetyNon-sterileNote:-Picture shown is of feed bag with flush set

Related Products

Here are some other products related to Covidien Kendall Kangaroo ePump Pump Sets,1000ml, Bag,Each,773656

Covidien Kendall Kangaroo ePump Pump Sets,1000ml, Bag,30/Case,773656

Blue Chip Rapid Air Alternating Pressure Gentle Low Air Loss Mattress System,Mattress System,Each,4300

Blue Chip Rapid Air Mattress Pump,10L x 5W x 4.5H,Each,4301

Blue Chip Rapid Air Alternating Pressure Mattress Overlay,35 x 80 x 5.5,Each,4320

Blue Chip Power-Turn Elite Lateral Rotation Therapy with True Low Air Loss Mattress System,42W x 80L x 9H,Each,9842

Industry News

If you're looking to sell or buy a waterfront home in Fairfield County Connecticut

For residential waterfront real estate in Stamford, Greenwich, Bridgeport, Branford, Milford, Darien, Westport, Norwalk, Fairfield, and New Haven Connecticut, click here to speak to a Fairfield County Realtor

>Read More

AstraZeneca & Daiichi drug wins another FDA approval, this time in lung cancer

On the heels of receiving a landmark FDA approval in breast cancer, AstraZeneca and Daiichi Sankyo drug Enhertu won an additional approval in non-small cell lung cancer. The decision makes the drug the first targeted NSCLC therapy addressing the cancer protein HER2. ...

>Read More

Report: PE firms' entrance into urgent care raises concerns for quality, affordability of care

Private equitys expanding presence in urgent care and the consolidation of the industry raise concerns about the quality and affordability of care, according to a recent report. It argued that the industry should be wary about this ownership trend, as private equity firms could cut staff, push costly procedures and strip out assets from providers. ...

>Read More

HealthEdge survey: Costs are top-of-mind for health plan leaders

When asked what their biggest difficulties are today, 46% of payer leaders said managing costs and 41% said driving operational efficiencies. The reason for this could be increasing claims volumes from the Covid-19 pandemic, rising costs from people delaying care and the use of outdated systems, the survey said. ...

>Read More

BCBS of Michigan teams up with Maven Clinic for virtual family, maternity care

Through the partnership, BCBSM fully-insured members will have access to Maven Maternity, and self-insured members can choose to add Maven’s full suite of solutions. This includes programs for family building, maternity or parenting and pediatrics. ...

>Read More

Materna Medical raises $22M to heal women's pelvic floors

Materna Medical, a company that sells Ob-gyn medical devices, recently raised $22 million in Series B funding. The round was raised by CEO Tracy MacNeal, which stands out because female founders raised just 2% of all venture capital money last year. ...

>Read More

Novartis warns of two patients deaths after dosing with gene therapy Zolgensma

The two deaths reported following treatment with Novartiss Zolgensma mark the first fatal cases of acute liver failure associated with the gene therapy. Liver complications are a known side effect risk of Zolgensma and other genetic medicines that are delivered by engineered viruses. ...

>Read More

What do GCs need to know right now about abortion trigger bans, HIPAA and how to not break the law?

In an exclusive interview, an attorney at McDermott Will & Emery’s Post-Roe practice group answers questions about how Texas’ trigger ban laws will impact employers, whether HIPAA protections apply to abortion access and the latest in Washington on rulemaking to strengthen ERISA preemption defense. ...

>Read More

Product Details for 10200-40841